Table 1.
Clinical characteristics of patients.
| ID | Age (years) | Sex | Ethnic origin | Genotype | HBsAg (log IU/ml) | HBeAg | HBeAb | HBV DNA (log IU/ml) | HBcrAg (log U/ml) | HBV RNA (log IU/ml) | ALT | Ishak fibrosis stage (/6) | EASL category | Additional notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 259 | 30 | Male | Caucasian – European | D | 4.88 | Neg | Pos | 2.19 | 3.7 | N.D. | 55 | 2 | HBeAg− chronic hepatitis | Nil |
| 262 | 30 | Female | Asian – Bangladeshi | n.d. | 4.34 | Pos | Neg | 9.88 | 9.1 | 8.8 | 100 | 3 | HBeAg+ chronic hepatitis | Nil |
| 265 | 33 | Male | Asian – Bangladeshi | D | 3.77 | Neg | Pos | 3.98 | 3 | N.D. | 34 | 1 | HBeAg− chronic hepatitis | Nil |
| 267 | 59 | Male | Asian – Bangladeshi | n.d. | 2.81 | Neg | Pos | 3.15 | <2 | d.n.q. | 13 | 0 | HBeAg− chronic infection | Nil |
| 279 | 35 | Male | Asian – Bangladeshi | C | 1.41 | Pos | Neg | 5.16 | 6.6 | 3.5 | 65 | 3 | HBeAg+ chronic hepatitis | Nil |
| 280 | 35 | Male | Asian – Pakistani | n.d. | 3.89 | Pos | Neg | 1.30 | 5.3 | 2.8 | 54 | 2 | HBeAg+ chronic hepatitis | On treatment (TDF) |
| 281 | 42 | Male | Afro Caribbean | n.d. | 2.26 | Neg | Pos | 1.79 | 3 | N.D. | 35 | 1 | HBeAg− chronic hepatitis | Nil |
| 283 | 22 | Male | Afro Caribbean | E | 4.16 | Pos | Neg | 5.67 | 5.5 | 2.6 | 25 | 2 | HBeAg+ chronic hepatitis | Nil |
| 284 | 33 | Male | Asian – Bangladeshi | A | 4.42 | Neg | Pos | 4.64 | 4 | 1.8 | 19 | 1 | HBeAg− chronic hepatitis | Nil |
| 285 | 54 | Female | Caucasian | — | — | — | — | — | — | — | 69 | n.d. | — | AIH; portal-based inflammation |
| 52 | 67 | Female | Caucasian | — | — | — | — | — | — | — | 47 | 1 | — | Cytolysis |
| 59 | 52 | Female | Caucasian | — | — | — | — | — | — | — | 67 | 1 | — | Cytolysis, steatosis 5% |
AIH, autoimmune hepatitis; ALT, alanine aminotransferase; d.n.q., detected, not quantified; HBcrAg, hepatitis B core-related antigen; HBeAb, hepatitis B e antibody; n.d., not determined; N.D., not detected; TDF, tenofovir disoproxil fumarate.